Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Pliant Therapeutics (PLRX) EBITDA Margin (2020 - 2023)

Pliant Therapeutics has reported EBITDA Margin over the past 4 years, most recently at 16976.61% for Q2 2023.

  • Quarterly EBITDA Margin fell 1637820.0% to 16976.61% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 68508.47% through Mar 2024, down 6714534.0% year-over-year, with the annual reading at 10065.38% for FY2023, 877392.0% down from the prior year.
  • EBITDA Margin was 16976.61% for Q2 2023 at Pliant Therapeutics, down from 2771.85% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 38.32% in Q1 2020 and troughed at 16976.61% in Q2 2023.
  • The 4-year median for EBITDA Margin is 1256.04% (2021), against an average of 2357.95%.
  • Year-over-year, EBITDA Margin soared 67844bps in 2022 and then tumbled -1637820bps in 2023.
  • A 4-year view of EBITDA Margin shows it stood at 426.45% in 2020, then tumbled by -190bps to 1235.22% in 2021, then crashed by -42bps to 1758.98% in 2022, then crashed by -865bps to 16976.61% in 2023.
  • Per Business Quant, the three most recent readings for PLRX's EBITDA Margin are 16976.61% (Q2 2023), 2771.85% (Q1 2023), and 1758.98% (Q4 2022).